


S/N 09/234532

PATENT



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Alfred Sapse  
Serial No.: 09/234532  
Filed: January 21, 1999  
Title: Compositions of Anti-HIV & Anti-Cortisol Compounds & Methods for Decreasing the Side Effects of Anti-HIV Drugs in a Human

Examiner: Unknown  
Group Art Unit: 1623  
Docket: 1941.006US1

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicant requests that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication.

Pursuant to 37 C.F.R. § 1.97(b), it is believed that no fee or statement is required with the Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Information Disclosure Statement considered.

INFORMATION DISCLOSURE STATEMENT

Serial No :09/234532

Filing Date: January 21, 1999

Title: Compositions of Anti-HIV & Anti-Cortisol Compounds & Methods for Decreasing the Side Effects of Anti-HIV Drugs in a Human

Page 2

Dkt: 1941.006US1

The Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

ALFRED SAPSE

By his Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.  
P.O. Box 2938  
Minneapolis, MN 55402  
(612) 373-6903


Date 5-4-04

By Warren D. Woessner

Warren D. Woessner  
Reg. No. 30,440

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 10th day of May, 2004.

PATRICIA A. HULTMAN  
Name

  
Signature

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		<b>Complete if Known</b> <b>Application Number</b> 09/234532 <b>Filing Date</b> January 21, 1999 <b>First Named Inventor</b> Sapse, Alfred <b>Group Art Unit</b> 1623 <b>Examiner Name</b> Unknown				
Sheet 1 of 1		Attorney Docket No: 1941.006US1				

**US PATENT DOCUMENTS**

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
	US-4,956,391	09/11/1990	Sapse, A	514	810	08/17/1988

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T <sup>2</sup>

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		BHANSALI, A, et al., "A preliminary report on basal & stimulated plasma cortisol in patients with acquired immunodeficiency syndrome," <u>Indian J Med Res.</u> , 112, (Nov. 2000),173-7	
		CHRISTEFF, N, et al., "Changes in cortisol/DHEA ratio in HIV-infected men are related to immunological and metabolic perturbations leading to malnutrition and lipodystrophy," <u>Ann N Y Acad Sci.</u> , 917, (2000),962-70	
		CORLEY, P A., "Acquired immune deficiency syndrome: the glucocorticoid solution," <u>Med Hypotheses</u> , 47 (1), (July 1996),49-54	
		XU, J, et al., "Inhibition of adrenal cortical steroid formation by procaine is mediated by reduction of the cAMP-induced 3-hydroxy-3-methylglutaryl-coenzyme A reductase messenger ribonucleic acid levels," <u>J Pharmacol Exp Ther.</u> , 307(3), Epub 2003 Oct 14.,(Dec. 2003),1148-57	

**EXAMINER****DATE CONSIDERED**